ANNOUNCING PARTNERSHIP AS VENTURE DEVELOPER TO MED4CAST TO PROMOTE THE USE OF AI IN MEDICAL DIAGNOSTICS
Katalysen Ventures is pleased to announce that we have formed a partnership as a venture developer to Swiss digital medtech startup Med4Cast. As a venture developer, Katalysen Ventures has been invited to participate as a co-founder and to invest approximately €12’000 (CHF12’500) at par value. This investment has now been completed, and Katalysen Ventures now owns 20% of Med4cast as a result.
Katalysen has been working for more than a year with leading medical, imaging and artificial intelligence experts on developing technology for advanced, machine based, diagnostics in orthopaedics. Given the encouraging results, Katalysen has decided to accept the invitation to participate as a co-founder in Swiss medtech startup Med4cast which has been incorporated to encapsulate current and develop future intellectual property generated from the enterprise. The vision of Med4cast is to become the leading AI diagnostic solution for specific medical fields, starting with orthopaedics.
Med4cast has access to large databases of medical data, consisting of patient data and images, which were built by our medical partners over decades. It is Katalysen’s view that this data gives Med4cast a competitive advantage, as few such detailed medical databases exist in orthopaedics.
Co-founders of Med4cast include Dr. Alex Lädermann, founder of BeeMed, investor in Katalysen Ventures, Dr. Frank Kolo, co-founder of Radix, and the medical software company Kisano, led by Mr. Serge Rovenne. Moreover, Med4cast cooperates with leading research facilities, and has a cooperation with IDIAP and UB Belgium.
IDIAP is a leading institute in voice and visual recognition, machine learning, human-machine interaction, robotics, language analysis, or bio-imaging. IDIAP was founded by the City of Martigny, the Canton du Valais, EPFL, the University of Geneva, and Swisscom. Other partners include ULB University in Belgium and the Jules Gonin Hospital.
Collaboration possibilities are also discussed with ID4, which uses an advanced and unique visualization software developed at CERN. IDE4 and CERN were introduced by Katalysen to Med4cast.
Heiner Weber from Katalysen will act as the Chairman of the Board, and Med4cast is an example of how Katalysen converts expertise into equity stakes in promising ventures.
This investment into Med4cast is expected to have a small (less than 10%) impact on Katalysen Ventures’ total value today, and as such is not considered inside information.
For more information on Katalysen, please contact:
CEO Peter Almberg
Phone: +46 76 860 37 00
E-mail: contact@katalysen.com
Web: www.katalysen.com
Katalysen Ventures AB (publ)
Katalysen Ventures is a Swedish venture capital company, founded by entrepreneur and company builder Peter Almberg. The Company operates as a so called “venture developer”. This means that Katalysen invests its expertise to reduce the risk level of its clients in exchange for stock options in the client company. Katalysen has eleven venture builders operating out of offices in Stockholm, Sweden and Geneva, Switzerland. Katalysen has so far invested its expertise and capital in 25 businesses.
Tags:
